Warning: Illegal string offset 'sidebar' in /home/customer/www/ on line 498

    Warning: Illegal string offset 'home' in /home/customer/www/ on line 498

    Warning: Illegal string offset 'home' in /home/customer/www/ on line 500

    Warning: Illegal string offset 'home' in /home/customer/www/ on line 504

    Warning: Illegal string offset 'sidebar' in /home/customer/www/ on line 516

    Warning: Illegal string offset 'home' in /home/customer/www/ on line 516

    Warning: Illegal string offset 'home' in /home/customer/www/ on line 518

    Emyria secures MDMA supply for therapy trial

    Emyria (ASX:EMD) has secured the supply of locally-available MDMA — meaning it’s now set to being dosing for its MDMA-assisted therapy (MDMA-AT) trial for post-traumatic stress disorder (PTSD). 

    This supply comes through a collaboration between Mind Medicine Australia (MMA) and the Australian National University (ANU), which will help ensure the ‘timely’ commencement of the trial while awaiting a comprehensive shipment from Canada. 

    Emyria says recently released results from a second phase three clinical trial on MDMA-AT for PTSD conducted by the Multidisciplinary Association for Psychedelic Studies further affirm the potential of the treatment. 

    The $26.79 million market capitalisation company says 86.5% of participants in the MDMA therapy group noted improved symptoms, and 71.2% of participants no longer met the criteria for PTSD following treatment. 

    Commenting on the MDMA supply, Emyria Chief Executive Officer (CEO) Michael Winlo says: “With our recent milestones, including the Pax Centre acquisition, our team’s training, and ethics approval, MDMA supply was the final component. 

    We are grateful to MMA and the ANU for their support in securing an immediately available initial supply, which ensures we can continue progress while we wait for our subsequent larger shipment from Canada pending approval from Health Canada.”

    MDMA supply was the final component”

    Mind Medicine Australia Chair and Co-founder Peter Hunt AM says: “A primary mission at MMA is to catalyse and support research into the potential of psychedelic medicines to address unmet needs in mental health treatments. 

    We’re pleased to assist Emyria and believe that collaborative efforts like these position Australia at the forefront of global advancements in mental health research.”

    Emyria is a clinical services and drug development company focused on revolutionising patient outcomes in neuroscience and mental health. 

    As of 30 June 2023, the company had $2.733 million cash and cash equivalents at hand, according to the latest quarterly report. Subsequent to the end of June, Emyria launched a placement to raise $3.1 million and completed an acquisition of the Pax Centre valued at $1.7 million.

    Write to Aaliyah Rogan at

    Images: Emyria Limited
    Aaliyah Rogan
    Aaliyah Rogan
    Recently relocated from a small town in New Zealand to Queensland Australia, Aaliyah Rogan is a fervent journalist who recently completed a Communications/Media degree at Otago University. Aaliyah hopes to excel as a journalist and become an inspiration to others.